# Bioequivalence Study to Compare Cariprazine 1.5 mg Hard Capsules (1.5 mg Cariprazine Hydrochloride) Versus Reagila® 1,5 mg Hartkapseln (Hard Capsules) (Cariprazine)

> **NCT07691190** · PHASE1 · COMPLETED · sponsor: **Humanis Saglık Anonim Sirketi** · enrollment: 32 (actual)

## Conditions studied

- SCHIZOPHRENIA 1 (Disorder)

## Interventions

- **DRUG:** Cariprazine Hard Capsules
- **DRUG:** Reagila® Hartkapseln (Hard Capsules) (Cariprazine)

## Key facts

- **NCT ID:** NCT07691190
- **Lead sponsor:** Humanis Saglık Anonim Sirketi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2026-03-05
- **Primary completion:** 2026-06-02
- **Final completion:** 2026-06-26
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2026-07-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07691190

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07691190, "Bioequivalence Study to Compare Cariprazine 1.5 mg Hard Capsules (1.5 mg Cariprazine Hydrochloride) Versus Reagila® 1,5 mg Hartkapseln (Hard Capsules) (Cariprazine)". Retrieved via MORVS 2026-10-21 from https://api.morvs.ai/clinical/NCT07691190. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*